Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Key Highlights
- ➤Q3 license and collaboration revenue $274.4 million, up from $4.7 million
- ➤Q3 net income $220.0 million versus $39.3 million net loss
- ➤MIMRYLO approval triggered $275 million in Takeda payments
- ➤Cash, equivalents and marketable securities reached $834.6 million
- ➤Board authorized a share repurchase program of up to $300 million
Expert Statements
Dinesh V. Patel, President and Chief Executive Officer of Protagonist Therapeutics
“The third quarter was a defining period for Protagonist, with FDA approval of MIMRYLO, our second approval this year for a first-in-class peptide drug, and the continued strong commercial launch of ICOTYDE under our collaboration with Johnson & Johnson”
Dinesh V. Patel, President and Chief Executive Officer of Protagonist Therapeutics
“MIMRYLO reflects years of disciplined scientific dedication and clinical execution, and together with ICOTYDE, provides immensely important validation both of our innovative expertise in peptide therapeutics and of the successful pharma-biotech partnership model we have built around these two approved drugs.”
Dinesh V. Patel, President and Chief Executive Officer of Protagonist Therapeutics
“The partnerships are fueling an accelerating revenue engine, which provides the flexibility to fund the next generation of wholly owned programs emerging from our platform, and to return meaningful capital to shareholders through a share repurchase program.”
NEWARK, CA / ACCESS Newswire / November 5, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.
"The third quarter was a defining period for Protagonist, with FDA approval of MIMRYLO, our second approval this year for a first-in-class peptide drug, and the continued strong commercial launch of ICOTYDE under our collaboration with Johnson & Johnson," said Dinesh V. Patel, PhD, President and Chief Executive Officer of Protagonist Therapeutics. "MIMRYLO reflects years of disciplined scientific dedication and clinical execution, and together with ICOTYDE, provides immensely important validation both of our innovative expertise in peptide therapeutics and of the successful pharma-biotech partnership model we have built around these two approved drugs. The partnerships are fueling an accelerating revenue engine, which provides the flexibility to fund the next generation of wholly owned programs emerging from our platform, and to return meaningful capital to shareholders through a share repurchase program."
Get started
Create a free account to read the full story.